15 Januari, 2001


Ranbaxy Laboratories Limited merupakan syarikat pengeluar produk perubatan yang terbesar di India yang telah ditubuhkan pada tahun 1961. Sebuah syarikat bersepadu berasaskan penyelidikan produk perubatan antarabangsa yang mengeluarkan pelbagai ubat-ubat yang berkualiti dan dipercayai oleh pengamal perubatan profesional untuk penjagaan kesihatan dan pesakit seluruh dunia.

Ranbaxy Malaysia Sdn Bhd telah ditubuhkan sebagai sebuah anak syarikat milik penuh pada bulan Jun 1984.

Dengan jualan yang cemerlangnya dan pasukan pemasaran yang berpengalaman dan berpengetahuan dengan industri, syarikat ini kini mempunyai pengiktirafan jenama yang kukuh dikalangan pengamal perubatan, hospital kerajaan dan rangkaian farmasi seluruh Malaysia. Pemasaran dan pengedaran produk juga dijalankan untuk Schwarz Pharma Desitin (Jerman) dan Pharmascience (Kanada).

Company Profile

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. The Company is ranked amongst the top ten global generic companies and has a presence in 23 of the top 25 pharma markets of the world. The Company with a global footprint in 49 countries, world-class manufacturing facilities in 11 and a diverse product portfolio, is rapidly moving towards global leadership, riding on its success in the world’s emerging and developed markets.


Ranbaxy was incorporated in 1961 and went public in 1973. For the year 2007, the Company's Global Sales at US$ 1,619 Mn reflected a growth of 21%. Profit after Tax at US$ 190 Mn registered an increase of 67% over the previous year.

The Company has a balanced mix of revenues from developed and emerging markets and is well positioned to leverage the growth potential offered by these markets. For the year 2007, North America, the Company's largest market contributed sales of US$ 419 Mn, contributing 26% of total sales followed by Europe garnering US$ 365 Mn. The Company’s business in Asia was led by a strong performance in India that clocked sales of US$ 301 Mn with market leadership backed by its strong brand-building skills.


Ranbaxy is focussed on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes. It continues to evaluate acquisition opportunities in India, emerging and developed markets to accentuate its business and competitiveness. The Company’s growth is well spread across geographies with near equal focus on developed and emerging markets. Ranbaxy has entered into new speciality therapeutic segments like Bio-similars, Oncology, Peptides and Limuses. These new growth areas will add significant depth to its existing product pipeline.


Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide the company with a sustainable, long-term competitive advantage. The Company today has a pool of over 1,200 scientists engaged in path-breaking research.

Ranbaxy is among the few Indian pharmaceutical companies in India to have initiated its research program in the late 70’s. To support its global ambition, a first of its kind world class R&D centre was commissioned in 1994. Today, the Company’s multi-disciplinary R&D centre at Gurgaon, in India, houses dedicated facilities for generics research and innovative research. The Company’s robust R&D environment for both drug discovery & development reflects the Company’s commitment to be a leader in the generics space and offer value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes.

Ranbaxy has enhanced its focus on NCE research with the proposed De-merger of its New Drug Discovery Research (NDDR) unit into a separate entity, Ranbaxy Life Science Research Ltd, subject to requisite approvals. This significant step will open up new growth opportunities and provides a platform for increased collaboration.

The new drug research areas at Ranbaxy include anti-infectives, inflammatory / respiratory, metabolic diseases, oncology, urology and anti-malaria. Presently, the Company has 8-10 programs comprising one anti-malaria molecule in Phase-II clinical trials. The Company has two programs in Phase I and the remaining in the pre-clinical stage. This includes a collaborative research program with GSK.

The company's NDDS focus is mainly on the development of NDA/ANDAs of oral controlled- release products for the regulated markets. The Company’s first significant international success using the NDDS technology platform came in September 1999, when Ranbaxy out-licensed its first once-a-day formulation to a multinational company.

Vision & Aspiritions

The Company is driven by its vision to achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets. It aspires to be amongst the Top 5 global generic players and aims at achieving global sales of US $5 Bn by 2012.


The Company’s business philosophy based on delivering value to its stakeholders constantly inspires its people to innovate, achieve excellence and set new global benchmarks. Driven by its vision to become a global leader the Company reinvents itself to achieve sustained growth and leadership.

Driven by the passion of its over 12,000 strong multicultural workforce comprising 50 nationalities, Ranbaxy continues to aggressively pursue its mission to become a Research-based International Pharmaceutical Company and attain a true global leadership position.

Released by Corporate Communications, April 2008

For more information log on to www.ranbaxy.com


Related Posts Plugin for WordPress, Blogger...